Compare Charles River Laboratories Intl. Inc (CRL) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Microsoft — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Microsoft trades at $528.2 (market cap $3.88T). The key difference: Microsoft is far larger — about 272.7× Charles River Laboratories Intl. Inc's market cap, and Microsoft pays a 0.75% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Microsoft for 142 Days on average.
| CRL | MSFT | |
|---|---|---|
Market Cap | $14.23B | $3.88T |
Volume | 1,176,885 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $310.77 | $542.07 |
52-Week Low | $149.93 | $352.83 |
Typical Hold Time | 33 Days | 142 Days |
Enterprise Value | $17.06B | $3.86T |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Microsoft trades at $529.76, up 0.09% with strong bullish technical signals and consistent earnings beats. The company maintains robust fundamentals with $281.72B revenue, 40.31% net margin, and positive cash flow. Recent analyst coverage shows 82% buy ratings with a $571.76 consensus target, while technical indicators suggest support at $526 and resistance at $533.
Outlook remains positive with AI leadership driving growth, though elevated P/E of 29.11 and competitive pressures present risks. The stock offers solid dividend income and institutional support, but investors should monitor capital expenditure trends and market rotation away from mega-cap tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
